Saxenda Approved for Weight Management New Phase 3a data indicates that overweight or obese adults with comorbidities had greater improvements in weight loss, fasting plasma glucose (FPG), systolic ...

Novo Nordisk announced the launch of Saxenda (liraglutide [rDNA origin]) injection as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult ...

Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade PLAINSBORO, N.J., Dec. 4, 2020 /PRNewswire/ -- Novo Nordisk today ...

In the ever-evolving symphony of weight loss medications, Saxenda (Liraglutide) has long taken center stage as a virtuoso in pharmaceutical solutions for shedding unwanted pounds. Yet, the search for ...